
FDA decision: Saroglitazar by Zydus Therapeutics (in 2026)
This market resolves based on the FDA's approval decision for Saroglitazar by Zydus Therapeutics in 2026.
Outcomes
Yes pays $1 if it happens · best price highlighted
| Outcome | Chance | 24h | Last 24h | |
|---|---|---|---|---|
| a full approval or an accelerated approval | 77% | — | 80¢ |
a full approval or an accelerated approval
77%
—Yes price on Kalshi, last 2 weeks
Discussion
Posts and calls about this event
Live room
Connecting…Loading…
Sign in to chat in the room.